Shares of Kala Pharmaceuticals, Inc. (KALA) are rising more than 6% Friday morning at $16.43.
The company today said Combangio, Inc., a unit of Kala, has been awarded a $15 million grant by the California Institute for Regenerative Medicine (CIRM) to support the company’s ongoing study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED).
KALA has traded in the range of $3.54-$56.72 in the last 1 year.
Source: Read Full Article
Lates News:
-
Bitcoin Lingers Above $17,000 Amid Macroeconomic, Recession Concerns For 2023
-
Recent Survey Shows Investors Think BTC Is More Likely To Crash To $10,000 First Than Hit $30,000
-
Bitcoin ($BTC) Price to Rise to $30,000 in Second Half of 2023, VanEck Says
-
Yusko on BlackRock's Bitcoin ETF & Crypto Future"
-
Bitcoin Predicted To Soar Past $35,000 By Summer As Wallets Holding At Least 1 BTC Hits The 1 Million Mark